SENTI-202
SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Hematological Malignancies
What will happen during the trial?
This is a dose-finding study of SENTI-202, comprised of an initial dose finding using a modified "3+3" study design to determine the maximum tolerated dose (MTD) and recommended phase two dose (RP2D) of SENTI-202 when administered after lymphodepleting chemotherapy (Part 1) followed by disease-specific expansion cohorts at the RP2D (Part 2).
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 21 patients (estimated)
- Sponsors
- Senti Biosciences
- Tags
- Natural Killer (NK) Cells (Allogeneic), CD33, FLT3
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1857
- NCT Identifier
- NCT06325748
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.